[1]Caroli A1, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to head comparison[J]. J Nucl Med, 2012, 53(4): 592-600.
[2]Klunk WE, Engler H, Nordberg A, et al． Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B[J]． Ann Neurol, 2004, 55(3): 306-319．
[3]Buckner RL, Snyder AZ, Shannon BJ, et al． Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory[J]． J Neurosci, 2005, 25(34): 7709-7717．
[4]Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI[J]. Neurobiol Aging, 2011, 32(7): 1207-1218.
[5]左传涛，刘永昌，管一晖，等. 年龄对脑葡萄糖代谢的影响[J]. 中国医学计算机成像杂志，2001，7（3）：204-206.
[6]Herholz K, Salmon E, Perani JC, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multi-center FDG PET[J]. Neuroimage, 2002, 17(1): 302-316.
[7]Ishii K, Sasaki M, Kitagaki H, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease[J]. J Nucl Med, 1997, 38(6): 925-928.
[8]Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13(6): 614-629.
[9]Mega MS, Cummings JL, O’Connor SM, et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease[J]. Neuropsychiatry Neuropsychol Behav Neurol, 2001, 14(1): 63-68.
[10]Pagani M, Dessi B, Morberlli S, et al. MCI patients declining and declining at mid-term follow-up: FDG-PET findings[J]. Curr Alzheimer Res, 2010, 7(4): 287-294.
[11]Chetelat G, Eustache F, Viader F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment[J]. Neurocase, 2005, 11(1): 14-25.
[12]Mosconi L, Tsui WH, Herholz K, et al． Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias[J]． J Nucl Med, 2008, 49(3): 390－398．
[13]Del Sole A, Clerici F, Chiti A, et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study[J]. Eur J Nucl Med Mol Imaging, 2008, 35(7): 1357-1366.
[14]华逢春，冯晓源，赵倩华，等. 轻度认知障碍及阿尔茨海默病脑葡萄糖代谢改变的统计参数图的PET研究[J]. Chin J Clin Neurosci，2013，21（2）：126-132.
[15]Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET[J]. J Nucl Med, 2005, 46(10): 1625-1632.
[16]李祖贵，高硕，张本恕，等. AD型与非AD型变性痴呆大脑葡萄糖代谢的SPM分析[J]. 中华核医学杂志，2008，28（1）：13-16.
[17]Bonte FJ, Harris TS, Roney CA, et al. Differential diagnosis between Alzheimer’s and frontotemporal disease by the posterior cingulate sign[J]. J Nucl Med, 2004, 45(5): 771-774.
[18]Minoshima S, Foster NL, Sima AA, et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation[J]. Ann Neurol, 2001, 50(3): 358-365. [19]Okamura N, Arai H, Higuchi M. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer’s disease[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2001, 25(2): 447-456.
[20]Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging[J]. J Nucl Med, 2004, 45(4): 594-607.
[21]Henriksen G, Yousefi BH, Drzezga A, et al. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography[J]. Eur J Nucl Med Mol Imaging, 2008, 35(Suppl 1): S75-S81.
[22]Cai L, Innis RB, Pike VW. Radioligand development for PET imaging of beta-amyloid(Abeta)-current status[J]. Curr Med Chem, 2007, 14(1): 19-52.
[23]Mathis CA, Bacskai BJ, Kajdasz ST, et al． A lipophilic thioavin-T derivative for positron emission tomography(PET) imaging of amyloid in brain[J]． Bioorg Med Chem Lett, 2002, 12(3): 295-298．
[24]Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B[J]. Ann Neurol, 2004, 55(3): 306-319.
[25]Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B(11C-PIB)and fluorodeoxyglucose(18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls[J]. J Geriatr Psychiatry Neurol, 2010, 23(3): 185-198.
[26]Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PiB PET study[J]. Neurology, 2009, 73(10): 754-760.
[27]Forsberg A, Engler H, Almkvist O, et al． PET imaging of amyloid deposition in patients with mild cognitive impairment[J]． Neurobiol Aging, 2008, 29(10): 1456-1465．
[28]Kadir A, Nordberg A． Target-specic PET probes for neurodegenerative disorders related to dementia[J]． J Nucl Med, 2010, 51(9): 1418-1430．
[29]Forsberg A, Engler H, Almkvist O, et al． PET imaging of amyloid deposition inpatients with mild cognitive impairment[J]． Neurobiol Aging, 2008, 29(10): 1456-1465．
[30]Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia[J]. Eur J Nucl Med Mol Imaging, 2008, 35(1): 100-106.
[31]王颖，高硕，蔡莉，等. 18F-FDG和11C-PIB PET联合脑显像对阿尔茨海默病及额颞痴呆的鉴别诊断价值初探[J]. 天津医药，2013，41（5）：401-403.
[32]Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease[J]. Brain, 2006, 129(11): 2856-2866.
[33]Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease[J]. Neurobiol Aging, 2012, 33(1): 198. e1-14.